Advertisement
The acquisition brings together Lipomics' metabolite profiling technologywith Tethys' proven expertise in the use of protein biomarkers to create noveltests capable of accurately predicting a person's likelihood of developingchronic diseases. Tethys launched its first such test - the PreDx(TM) DiabetesRisk Test - earlier this year, and is working to develop similar tests thatwill predict a person's likelihood of experiencing an osteoporotic bonefracture or a major cardiac event.
Advertisement
Integration of the Lipomics understanding of lipid biology with the Tethysprotein biomarker analysis capability provides the Company with state-of-the-art technology as it extends its focus beyond diabetes. With this combination,Tethys is uniquely positioned to develop unprecedented insights into thebiological mechanisms of a host of diseases.
"We are very excited to add this highly complementary expertise to ourincreasingly diversified technology portfolio," said Mickey Urdea, Tethys'founder, chairman and CEO. "We believe that the best solutions for predictingand thereby preventing a range of chronic conditions will come from thethoughtful integration of multiple types of biomarkers - including proteinsand metabolites. The addition of Lipomics furthers our goal of arming patientsand physicians with insights that will help reduce the incidence ofpreventable chronic diseases."
With completion of the acquisition today, full integration of thecompanies is well underway. Effective today, all 30 employees of Lipomics willbecome part of Tethys. Steven M. Watkins, PhD., co-founder, president andchief scientific officer of Lipomics, will assume the role of chief technologyofficer at Tethys. The Lipomics facility will continue its comprehensive andquantitative profiling of lipid metabolites as Tethys West Sacramento.
"From the moment we began discussions with Tethys, we were each struck bythe complementary nature of our technologies, our core skills, and our sharpfocus on addressing unmet clinical needs," Watkins said. "The Lipomics team isdelighted to become part of Tethys, and to bring our expertise to bear onadvancing the field of predictive personalized medicine."
About Tethys Bioscience
Tethys Bioscience is a predictive personalized medicine company developingnovel tests which address the growing global healthcare challenge of chronicdiseases such as diabetes. Founded in 2005, the company integrates anexperienced management team, innovative research based on sound science, aCLIA-licensed clinical laboratory, and a commercialization team with extensiveexperience in diagnostic innovation. Our partnerships with world classresearchers and our solid financial foundation will enable Tethys to helptransform the management of chronic diseases by providing personalized,preventive solutions that aid every constituency: patients, doctors and thehealthcare system as a whole.
About Lipomics
Lipomics Technologies provides industry-leading metabolic assessments fordrug research, clinical diagnostics and personalized medicine. The Company'sproprietary analytical technologies generate comprehensive, accurate andquantitative profiles of lipid metabolites. Lipomics delivers deep and richknowledge about biological and metabolic changes induced by disease, drugaction, nutritional or lifestyle influences. In partnership withpharmaceutical, biotechnology, and nutrition companies, Lipomics uses itstechnologies to discover new diagnostic biomarkers, improve drug discovery,develop companion diagnostics and enable individualized health management.
About the PreDx(TM) Diabetes Risk T
